Novolog (insulin aspart) NDC 0169-6338

Product information

Brand name (proprietary)

Novolog

Generic name (nonproprietary)

insulin aspart

Active ingredients

Insulin aspart — 100 [iU]/mL

Dosage form

Injection, Solution

Route

Intravenous, Subcutaneous

Labeler

Novo Nordisk

Product type

Prescription drug

Marketing category

BLA — Biologics License ApplicationApplication BLA 020986

Marketing start

Oct 31, 2013

Listing expires

Dec 31, 2026

Other FDA classes

Insulin (Chemical structure)

Identifiers

Product ID 0169-6338_de82c22d-ea25-44ef-8bcd-c3cda9e84e59SPL ID de82c22d-ea25-44ef-8bcd-c3cda9e84e59SPL set ID 3a1e73a2-3009-40d0-876c-b4cb2be56fc5RxCUI 311040, 351926, 1653196, 1653198, 1653202, 1653204UNII 059QF0KO0R, D933668QVX

Pharmacologic class

Insulin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

Product label

Other NDCs under BLA 020986

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.